SciELO - Scientific Electronic Library Online

vol.16 issue3Complications of carpal scaphoid fractures: magnetic resonance evaluationPharmacoeconomics of sugammadex for the reversal of neuromuscular relaxation under general anaesthesia at Ángeles Pedregal Hospital author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • Have no similar articlesSimilars in SciELO


Acta médica Grupo Ángeles

Print version ISSN 1870-7203


HURTADO MONROY, Rafael et al. Imatinib mesylate as first-line treatment in patients with chronic myeloid leukemia Philadelphia + (CML-Ph+) in accelerated phase (AF), compared to chronic phase (CF). A long-term retrospective study. Acta méd. Grupo Ángeles [online]. 2018, vol.16, n.3, pp.204-208. ISSN 1870-7203.


The accelerated phase is a condition of progression of the CML. Our first line of treatment is imatinib mesylate (IM); however, there is no information on long-term outcomes in AP.

Material and methods:

We conducted a retrospective comparative study of patients with CML Ph+. Patients with CP received IM 400 mg/day and patients with AP 600 mg/day, both were followed with cytogenetic studies with fluorescence in situ hybridization (FISH) (minimum 200 nuclei analyzed) every three months.


The median time for the complete cytogenetic response (CCyR) was eight months in CP and 12 months in AP. The length of this response in CP was 73 months in 100% of patients and 30 months in 42.9% of AP. The median survival (follow-up of 120 months) was 70 months in AP and 150 months in CP (p < 0.0001). The median long-term free-disease and overall survival was 73 months in CP and 30 months in AP.


The AP has lower CCyR and survival, which suggests the need to change the initial treatment.

Keywords : Chronic myeloid leukemia; imatinib; accelerated phase.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )